ISCOMATRIX super(TM) adjuvant: an adjuvant suitable for use in anticancer vaccines

• Published in: Vaccine Vol. 22; no. 27-28; pp. 3738 - 3743
• Main Authors: Stewart, T J, Drane, D, Malliaros, J, Elmer, H, Malcolm, K M, Cox, J C, Edwards, S J, Frazer, I H, Fernando, GJP
• Format: Journal Article
• Language: English
• Published: 01-09-2004
• Subjects: Human papillomavirus 16
• ISSN: 0264-410X
• DOI: 10.1016/j.vaccine.2004.03.026

Human Papillomavirus type 16 (HPV16) E6 and E7 oncoproteins are associated with cervical cancer development and progression and can therefore be used as target antigens for cancer immunotherapy. In this study we evaluated the immunogenicity in mice, of different vaccine formulations using recombinant HPV16 derived E6E7 or E7GST fusion proteins. When co-administered with ISCOMATRIX super(TM) adjuvant, these E6E7 proteins consistently induced E7 specific CTL, in vivo tumor protection, antibody and DTH responses. ISCOMATRIX super(TM) adjuvant has been developed for use in the formulation of novel human vaccines and has been evaluated for safety and toxicity in human trials. A formulation containing aluminum hydroxide (Al(OH) sub(3)) gave a lesser degree of E7 specific antibody, and no local E7 specific CTL response but similar DTH and tumor protection. These findings demonstrate the potential of ISCOMATRIX super(TM) adjuvant to stimulate both cellular and humoral immune responses to endogenously processed target antigens, and hence is the preferred adjuvant when CTL responses are desirable.